A man’s severe case of treatment-resistant immune thrombotic thrombocytopenic purpura (iTTP) — which resulted in severe anemia despite more than a week spent in…
Star Therapeutics‘ experimental therapy VGA039, developed to prevent bleeding in von Willebrand disease (VWD), has been granted both rare pediatric disease and breakthrough therapy status by U.S. regulators. These designations, awarded by the U.S. Food and Drug Administration (FDA), incentivize development of medications for serious and rare conditions…
Latest news & perspectives
People diagnosed with immune thrombotic thrombocytopenic purpura (TTP) in the U.S. report significant unmet healthcare needs, particularly related to mental health support and relapse…
